Search research articles
Contact Us
Filters
Showing results (101-110 of 109) with videos related to
Page
of 11
Sort By:
You have reached the last page of results.
This site can display upto 109 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 19, 2002
Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study
W Jonat, M Kaufmann, W Sauerbrei, et al.
Breast (Edinburgh, Scotland)
|
October 11, 2011
Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design
W Eiermann, J Bergh, F Cardoso, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 12, 2007
Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study
G von Minckwitz, S Kümmel, A du Bois, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 5, 2016
Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial
J R Mackey, T Pieńkowski, J Crown, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 14, 2007
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006
M Kaufmann, G von Minckwitz, H D Bear, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 24, 2013
Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial
C Denkert, S Loibl, B M Müller, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 21, 2018
Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial
J Ettl, R G W Quek, K-H Lee, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 24, 2020
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial
J K Litton, S A Hurvitz, L A Mina, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 19, 2014
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12
M Gnant, B Mlineritsch, H Stoeger, et al.
Page
of 11
Search research articles
Search
Showing results (101-110 of 109) with videos related to
Sort By:
Page
of 11
You have reached the last page of results.
This site can display upto 109 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 19, 2002
Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study
W Jonat, M Kaufmann, W Sauerbrei, et al.
Breast (Edinburgh, Scotland)
|
October 11, 2011
Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design
W Eiermann, J Bergh, F Cardoso, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 12, 2007
Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study
G von Minckwitz, S Kümmel, A du Bois, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 5, 2016
Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial
J R Mackey, T Pieńkowski, J Crown, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 14, 2007
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006
M Kaufmann, G von Minckwitz, H D Bear, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 24, 2013
Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial
C Denkert, S Loibl, B M Müller, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 21, 2018
Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial
J Ettl, R G W Quek, K-H Lee, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 24, 2020
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial
J K Litton, S A Hurvitz, L A Mina, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 19, 2014
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12
M Gnant, B Mlineritsch, H Stoeger, et al.
Page
of 11